Agenus incorporation

US StockHealth Care

AGEN AI Analysis Overview

Keys for Bullish View

  • Value≥4
  • Dividend≥2

Analysis Conclusion

The stock, with its moderate value rating, suggests that existing positions can be retained. For initiating new positions, it's advisable to wait for a value score above 4 and a dividend score of 2 or higher.

AGEN Current Performance


Agenus incorporation


Avg of Sector



Top 10 High Relevance to AGEN

  • APGE Apogee therapeutics inc
    Value -Trend 5Swing Trading 3Whale Interest 3Dividend 1
    See more

AGEN Profile

Agenus Inc. is a clinical-stage immuno-oncology (I-O) company. The Company is focused on the discovery and development of therapies that engage the body's immune system to fight cancer and infections. The Company's I-O assets include antibody-based therapeutics, monospecific and bispecific antibodies, cell therapy and vaccine adjuvants. The Company's antibody candidates are botensilimab (a CTLA-4 antibody, also known as AGEN1811) and balstilimab (a PD-1 antibody). Botensilimab is in three Phase 2 studies as a monotherapy (melanoma), in combination with chemotherapy (pancreatic cancer), and in combination with balstilimab (microsatellite stable colorectal cancer (MSS CRC)). Its clinical-stage portfolio also includes Botensilimab (AGEN1181), Balstilimab (AGEN2034), Zalifrelimab (AGEN1884), AGEN2373, AGEN1423, AGEN1571, MK-4830, INCAGN1876, INCAGN2390, INCAGN2385, BMS-986442, UGN-301, agenT-797 and QS-21 STIMULON. AGEN2373, a CD137 monospecific antibody in a Phase 1b clinical trial.

Price of AGEN